NBP
NovaBridge BiosciencesNASDAQHealthcare$2.43-1.22%ClosedMarket Cap: $280.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.92
P/S
0.00
EV/EBITDA
-3.76
DCF Value
$0.12
FCF Yield
0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-10.9%
ROA
-3.4%
ROIC
-4.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $0.00 | -Infinity% | $-64.0M | $-48.7M | $-0.48 | — |
| Q2 2025 | $0.00 | NaN% | $-7.1M | $-5.5M | $-0.07 | — |
| Q1 2025 | $0.00 | NaN% | $-5.3M | $-3.1M | $-0.28 | — |
| Q4 2024 | $0.00 | NaN% | $-13.4M | $-9.1M | $-0.11 | — |
| FY 2024 | $0.00 | NaN% | $-375.4M | $-162.3M | $-4.46 | — |
| Q3 2024 | $0.00 | NaN% | $-12.4M | $-20.5M | $-0.25 | — |
| Q2 2024 | $0.00 | NaN% | $-15.0M | $25.1M | $0.30 | — |
| Q1 2024 | $0.00 | NaN% | $-90.6M | $20.8M | $-0.85 | — |
| Q4 2023 | $1.1M | -1687.5% | $-174.9M | $-346.4M | $-4.16 | — |
| FY 2023 | $4.5M | 100.0% | $-511.2M | $-1.47B | $-17.62 | — |
| Q3 2023 | $4.0M | 100.0% | $-282.1M | $-346.4M | $-4.16 | — |
| Q2 2023 | $9.8M | 100.0% | $-335.9M | $-386.4M | $-4.65 | — |